Two schedules of etirinotecan pegol (NKTR-102) in patients with previously treated metastatic breast cancer: A randomised phase 2 study

The Lancet Oncology

Volumn 14, Issue 12, 2013, Pages 1216-1225

  Awada, Ahmad ^a   Garcia, Agustin A ^b   Chan, Stephen ^c   Jerusalem, Guy H M ^d   Coleman, Robert E ^e   Huizing, Manon T ^f   Mehdi, Aminder ^g   O'Reilly, Sue M ^h   Hamm, John T ⁱ   Barrett Lee, Peter J ^j   Cocquyt, Veronique ^k   Sideras, Kostandinos ^l   Young, David E ^m   Zhao, Carol ⁿ   Chia, Yen Lin ⁿ   Hoch, Ute ⁿ   Hannah, Alison L ⁿ   Perez, Edith A ^o  

^a JULES BORDET INSTITUTE   (Belgium)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^d UNIVERSITY OF LIÈGE   (Belgium)

^e CR UK YCR Cancer Research Centre   (United Kingdom)

^f ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^g Stockton Hematology Oncology Medical Group Inc   (United States)

^h CLATTERBRIDGE CENTRE FOR ONCOLOGY   (United Kingdom)

ⁱ Norton Health Care   (United States)

^j Velindre NHS Trust   (United Kingdom)

^k GHENT UNIVERSITY HOSPITAL   (Belgium)

^l MAYO CLINIC   (United States)

^m Desert Hematology Oncology Medical Group   (United States)

ⁿ NEKTAR THERAPEUTICS   (United States)

^o MAYO CLINIC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; ANTHRACYCLINE; ANTIDIARRHEAL AGENT; BEVACIZUMAB; CAPECITABINE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETIRINOTECAN PEGOL; GLUCURONOSYLTRANSFERASE 1A1; LAPATINIB; MITOXANTRONE; PACLITAXEL; TAXANE DERIVATIVE; TRASTUZUMAB;

ABCC2 GENE; ABDOMINAL PAIN; ACUTE KIDNEY FAILURE; ADULT; AGED; ALOPECIA; ANEMIA; ANTICHOLINERGIC SYNDROME; ARTICLE; BLURRED VISION; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CONSTIPATION; CONTROLLED STUDY; DECREASED APPETITE; DEHYDRATION; DIARRHEA; DIZZINESS; DNA POLYMORPHISM; DOSAGE SCHEDULE COMPARISON; DRUG METABOLISM; DRUG SAFETY; DRUG WITHDRAWAL; DYSGEUSIA; DYSPNEA; EPIPHORA; FATIGUE; FEMALE; FEVER; GENE MUTATION; HEADACHE; HOMOZYGOTE; HUMAN; HYPERSALIVATION; LETHARGY; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHARMACOGENETICS; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEPTIC SHOCK; SIDE EFFECT; THROMBOCYTOPENIA; UGT1A1 GENE; UPPER ABDOMINAL PAIN; VOMITING; WEIGHT REDUCTION; XEROSTOMIA;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CAMPTOTHECIN; DRUG ADMINISTRATION SCHEDULE; EUROPE; FEMALE; HETEROCYCLIC COMPOUNDS WITH 4 OR MORE RINGS; HUMANS; INTENTION TO TREAT ANALYSIS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; POLYETHYLENE GLYCOLS; TIME FACTORS; TOPOISOMERASE I INHIBITORS; TREATMENT OUTCOME; UNITED STATES;

EID: 84886725282     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(13)70429-7     Document Type: Article

References (29)

1. Breast cancer facts and figures American Cancer Society, (accessed Aug 13, 2012). http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-030975.pdf.
2. Perez EA, Lerzo G, Pivot X, et al. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol 2007, 25:3407-3414.
3. Cortes J, Vahdat L, Blum JL, et al. Phase II study of the halichondrin b analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine. J Clin Oncol 2010, 28:3922-3928.
4. Von Hoff DD, Jameson GS, Borad MJ, et al. First phase I trial of NKTR-102 (PEG irinotecan) reveals early evidence of broad anti-tumor activity in three schedules. Eur J Cancer 2008, 6(suppl):595.
5. Jameson GS, Hamm JT, Weiss GJ, et al. A multicenter, phase 1, open-label, dose-escalation study to assess the safety, tolerability, and pharmacokinetics of NKTR-102 in patients with refractory solid tumors. Clin Cancer Res 2013, 19:268-278.
6. Antonian L, Burton K, Goodin R, Bentley M, Eldon MA PEGylation governs the disposition and metabolism of irinotecan following administration of a novel PEG-irinotecan conjugate. Eur J Cancer 2007, 5(suppl):115.
7. Eldon MA, Antonian L, Staschen CM, et al. Anti-tumor activity and pharmacokinetics of a novel PEGylated-irinotecan, in irinotecan-resistant colorectal tumors implanted in mice. Eur J Cancer 2007, 5(suppl):114.
8. Eldon MA, Staschen CM, Viegas T, Bentley M. NKTR-102, a novel PEGylated irinotecan conjugate, results in sustained tumor growth suppression in mouse models of human colorectal and lung tumors that is associated with increased and sustained tumor SN38 exposure. Proceedings of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; San Francisco, CA, USA; 22-26 Oct, 2007. Abstr C157.
9. Persson H, Antonian L, Staschen CM, Viegas T, Bentley M. Polyethylene glycol conjugation of irinotecan improves its anti-tumor activity in three mouse xenograft models. Proceedings of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; San Francisco, CA, USA; 22-26 Oct, 2007. Abstr C10.
10. Persson H, Barker T, Eldon M, Wolff R. NKTR-102, a novel PEGylated-irinotecan, has a superior acute safety, tolerability, and pharmacokinetic profile compared to irinotecan in rats and dogs. Proceedings of AACR Annual Meeting; San Diego, CA, USA; April 12-16, 2008. Abstr 5742.
11. Persson H, Barker T, Eldon M, et al. NKTR-102, a novel PEGylated-irinotecan, has an enhanced pharmacokinetic profile with reduced gastrointestinal and hematopoietic toxicity compared to irinotecan with repeat dosing in dogs. Proceedings of AACR Annual Meeting; San Diego, CA, USA; April 12-16, 2008. Abstr 5741.
12. Hoch U, Masuoka L, Maslyar D, et al. NKTR-102 demonstrates nonclinical and phase 1 clinical anti-tumor activity in ovarian cancer. Eur J Cancer 2009, 7(suppl):454.
13. Perez E, Hillman DW, Mailliard JA, et al. Randomized phase II study of two irinotecan schedules for patients with metastatic breast cancer refractory to an anthracycline, a taxane, or both. J Clin Oncol 2004, 22:2849-2855.
14. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000, 92:205-216.
15. Denduluri N, Low JA, Lee JJ, et al. Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanes. J Clin Oncol 2007, 25:3421-3427.
16. Vahdat LT, Pruitt B, Fabian CJ, et al. Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2009, 27:2954-2961.
17. Thomas E, Tabernero J, Fornier M, et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. J Clin Oncol 2007, 25:3399-3406.
18. Cortes J, O'Shaughnessy J, Loesch D, et al. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet 2011, 377:914-923. for the EMBRACE (Eisai Metastatic Breast Cancer Study Assessing Physician's Choice Versus E7389) investigators.
19. Blum JL, Savin MA, Edelman G, et al. Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes. Clin Breast Cancer 2007, 7:850-856.
20. Burstein H, Elias AD, Rugo HS, et al. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2008, 26:1810-1816.
21. Barrios CH, Liu MC, Lee SC, et al. Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer. Breast Cancer Res Treat 2010, 121:121-131.
22. Moreno-Aspitia A, Morton RF, Hillman DW, et al. Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336. J Clin Oncol 2009, 27:11-15.
23. Ellard SL, Clemons M, Gelmon KA, et al. Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163. J Clin Oncol 2009, 27:4536-4541.
24. Roché H, Li RK, Ro J Ixabepilone plus capecitabine improves progression free survival in patients with metastatic breast cancer resistant to taxanes: a pooled analysis from two phase III trials. Cancer Res 2009, 69(suppl):2015.
25. Perez EA, Patel T, Moreno-Aspitia A Efficacy of ixabepilone in ER/PR/HER2 negative (triple negative) breast cancer. Breast Cancer Res Treat 2010, 121:261-271.
26. Pivot XB, Li RK, Thomas ES, et al. Activity of ixabepilone in oestrogen receptor-negative and oestrogen receptor-progesterone receptor, human epidermal growth factor receptor 2-negative metastatic breast cancer. Eur J Cancer 2009, 45:2940-2946.
27. Delaloge S, Tedesco KL, Blum J, et al. Preliminary safety and activity results of trabectedin in a phase II trial dedicated to triple negative (ER-, PR-, Her2-), Her2+++, or BRCA1/2 germline-mutated metastatic breast cancer (MBC) patients (pts). Proc Am Soc Clin Oncol 2009, 27(suppl):1010. (abstr).
28. Drug approval package: Halaven (eribulin mesylate) injection US Food and Drug Administration, (accessed Aug 13, 2012). http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/201532s000_halaven_TOC.cfm.
29. Schoemaker NE, Kuppens IELM, Moiseyenko V, et al. A randomised phase II multicentre trial of irinotecan (CPT-11) using four different schedules in patients with metastatic colorectal cancer. Br J Cancer 2004, 91:1434-1441.